机构:[1]Department of Tumor lmmunotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050035, China河北医科大学第四医院[2]Research Center and Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050017, China河北医科大学第四医院[3]The Third Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050011, China临床科室外三科河北医科大学第四医院[4]Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer. Shiiiazhuang.050011.China
The lack of diagnostic and therapeutic targets precludes effective treatment of esophageal cancer, rooted in the limited mechanistic understanding of cancer initiation and progression. Non-mutational epigenetic reprogramming, including altered 5-methylcytosine (m5C) modification and circular RNA (circRNA) expression, can drive tumorigenesis and impact cancer biology. Herein, we identified upregulation of the circRNA hsa_circ_0066658 (termed as circTMEM45A) in esophageal squamous cell carcinoma (ESCC) tissues, which was correlated with advanced clinical stages and poor survival. Functionally, elevated circTMEM45A facilitated ESCC malignant progression both in vitro and in vivo. Mechanistically, circTMEM45A interacted with the methyltransferase NSUN2 and m5C readers ALYREF and YBX1, promoting the nuclear export and stability of NLRP3 mRNA to activate the NLRP3/caspase 1/IL-1β inflammatory pathway. Additionally, circTMEM45A stabilized IL1B mRNA by binding to U2AF2 and stabilized IL1R1 mRNA by serving as a protein scaffold to enhance the IGF2BP2/HUR interaction, further activating the IL-1β/IL1R1 pro-inflammatory cascade in the tumor microenvironment. These findings reveal crosstalk between circRNA and m5C modification that drives inflammatory progression, highlighting circTMEM45A as a potential diagnostic and therapeutic target in ESCC.
基金:
This work was supported by the Hebei Provincial Government-funded Clinical
Talent Project (ZF2025194),and the National Natural Science Foundation of
China(No.82002577).
语种:
外文
PubmedID:
中科院分区:
出版当年[2025]版:
大类|1 区医学
小类|1 区肿瘤学
最新[2025]版:
大类|1 区医学
小类|1 区肿瘤学
第一作者:
第一作者机构:[1]Department of Tumor lmmunotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050035, China[2]Research Center and Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050017, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Meng Lingjiao,Wu Haotian,Wu Jiaxiang,et al.Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation[J].Cancer Research.2025,doi:10.1158/0008-5472.CAN-24-4154.